Lipid Polymer Hybrid Nanoparticles as an Efficient Hepatic Drug Delivery System

Abstract

In spite of the great development in the field of hepatology, CHB, is a major public health problem worldwide. Unfortunately, CHB is a major public health challenge in Egypt where 1.4% of the total population were diagnosed with HBV and millions are undiagnosed or at risk. E, a nucleoside reverse transcriptase inhibitor, is one of the first line potent antiviral therapies for HBV which could reduce the risk of virus progression to liver cirrhosis and hepatocellular carcinoma. Although its proved efficacy, E is accompanied with some drawbacks as high risk of resistance and serious adverse effects as neuropathy, skeletal and cardiac myopathy, nephrotoxicity, pancreatitis and lactic acidosis. Moreover, the high rate of non-compliance in patients with chronic diseases and long-life treatment are serious healthcare concerns that pose a great challenge to the successful delivery of pharmaceuticals.